Dr. Mary L. (Nora) Disis

powered by
COS Expertise®
University of Washington
School of Medicine
Medicine
Oncology
ProfessorAppointed: 2006
University of Washington
Translational Science
Associate DeanAppointed: 2007
University of Washington
Istitute for Translational Health Sciences
DirectorAppointed: 2007
Fred Hutchinson Cancer Research Center
Clinical Research Division
MemberAppointed: 2006
University of Washington
General Clincial Research Center
DirectorAppointed: 2004
University of Washington
School of Medicine
Center for Translational Medicine in Women's Health
DirectorAppointed: 2004
Professional Headshot of Mary L. (Nora) Disis

Mailing Address

815 Mercer Street
2nd Floor
Tumor Vaccine Group
Box 358050
Seattle, Washington 98109-8050
United States

Contact Information

Phone: (206) 616-1823
Fax: (206) 685-3128
ndisis@u.washington.edu

Qualifications

M.D./M.S, University of Nebraska, Immunology, 1986.

Expertise and Research Interests

Major projects include: (1) development of tumor antigen specific vaccines for the prevention of solid tumor relapse, (2) generation and characterization of cytotoxic CD8+ and CD4+ helper T cells specific for tumor antigens for eventual use in adoptive immunotherapy to treat advanced stage disease, (3) evaluation of antibody responses to various cancer causing proteins for use as a potential cancer diagnostic, (4) development of biologically relevant animal models for solid tumors to assess the effect of the generation of an immune response to immunogenic cancer proteins and to evaluate different vaccine and adoptive immunotherapy strategies, (5) phase I/II clinical trials of peptide and DNA vaccines targeting specific cancer antigens, (6) phase I/II clinical trials of infusion of antigen competent T cells in patients with advanced stage solid tumors, (7) antigen discovery in solid tumors using molecular immunology and protein based techniques, and (8) development of in vivo imaging techniques for tracking tumor specific T cells and assessing the response to tumor specific immunotherapy.

Studies from our laboratory have demonstrated that some patients with breast cancer have existent immunity to the HER-2/neu (H2N) protein which is the product of the amplified HER-2/neu oncogene. Therefore, the H2N protein is a tumor antigen. Developing immunotherapy targeting the H2N oncogenic protein via therapeutic vaccination and infusion of H2N specific T cells is a major goal of our work. We have identified breast cancer patients with both specific antibody and specific T cell responses to the protein. In addition, we have been able to generate cytotoxic T cells (CD8+) with an ability to specifically kill breast cancer cells via recognition of H2N protein. The detection of immunity to an oncogenic protein intimately involved in the growth and malignant potential of breast cancer has several profound ramifications. Methods to augment the existent immunity such as T cell therapy or vaccination might have a therapeutic effect. Our laboratory is currently evaluating the potential use ofH2N immunity inthe treatment of breast cancer, and is identifying potential target epitopes for T cell and vaccine therapy.

In addition to human studies, we have developed an animal model to study the effect of generating immunity to the H2N protein. One important feature of the H2N oncoprotein is that it is a non-mutated , overexpressed normal protein. The rat is an ideal model. Rat neu is 89% homologous to human H2N and the distribution of normal neu is similar, being found at low levels inskin and digestive tract epithelium. The major issues we are addressing in the rat model are how best to circumvent tolerance to H2N and whether levels of immunity necessary for tumor eradication cause any autoimmune toxicity. These studies should bedirectly applicable to humans as the structure, function, expression, and distribution of H2N is homologous in rats and humans. Results from these investigations will be directly applicable to the
treatment of breast cancer patients.

Extrapolatingfrom animal models of T cell therapy, treatment of human breast cancer should be possible provided that enough immune T cells can be generated and provided that the T cells are immune to the appropriate antigen. Theoretically, H2N is an appropriatetarget antigen. It is our hope that T cellvaccines an T cell therapy will be of benefit in cancer therapy, and, in addition, give the patient the ability to
protect against future relapse by the augmentation of her own immune defenses.

Cancer Vaccines
Tumor Immunology
Immunotherapy
T-Cell Therapy
Immunodiagnostics
HER - 2/neu
Antigen Discovery

Other Expertise

Breast Cancer
Ovarian Cancer

Keywords

COS Keywords:

Animal Models, Blood Or Blood Products Or Transfusions, Breast Cancer, Cancer or Carcinogenesis, Cancer Prevention, Hematology, Immunobiology, Immunology, Immunopathology, Immunophysiology, Immunotherapy, Lymphocytes, Medical Treatment, Mutagenesis, Mutation, Oncology, Tumor Immunology, Vaccine.

Additional Terms:

Blood, Blood Cells, Cancer, Cancer Vaccines, Diagnosis, Immunobiology, Immunology, Immunotherapy, Lymphocytes, Mutagenesis, Mutation, Oncology, Prevention, Therapy, Treatment, Tumor Biology, Tumor Immunology, White Cells.

Memberships

Alpha Omega Alpha
American Association for Cancer Research
American Association of Immunologists
American Society for Clinical Oncology
American Society of Hematology
Society of Biologic Therapy
Southwest Oncology Group
Women in Cancer Research

Honors and Awards

2007, Scholarship, American Association of Medical Schools Women's Facutly Seminar
2006-2008, Deputy Editor, Translational Oncology, Journal Clinical Oncology
2006, Science Forum Lecturer, University of Washington, College of Arts & Sciences
2006, Elected, Board of Directors, International Society of Biologic Therapy
2006, Award for Scientific Excellence, Cancer Treatment Research Foundation
2004, Elected, American Society of Clinical Investigation
2004-2006, Chair, Clinical Oncology Study Section (CONC), NIH/NCI
2003, Center of Women's Health Award for Outstanding Mentorship, University of Washington School of Medicine
2003, Celebrating Hope Award of Scientific Achievement, Olympic Medical Center Foundation
2001, Science in Medicine Lectureship, University of Washington College of Medicine
2000-2001, Mid-Career Investigator Award in Patient Oriented Research, National Cancer Institute
1995-2000, Clinical Investigator Award, National Cancer Institute
1995-2000, FIRST Award, National Cancer Institute
1995-2000, Clinical Investigator Award, Nathional Cancer Institute
1995, Science in Medicine, New Investigator Lectureship, University of Washington College of Medicine
1994-1996, ACS Physician Research Training Award,
1993-1995, Berlex Oncology Foundation Clinical Research Fellow,
1991, Upjohn Outstanding Oncology Fellow Award, University of Washington
1990-1991, Clinical Oncology Fellowship, American Cancer Society
1989, Alpha Omega Alpha,

Previous Positions

2001-2006, Associate Member, Fred Hutchinson Cancer Research Center, Clinical Division
1999-2006, Associate Professor, University of Washington, Division of Oncology
1998-2004, Director, University of Washington, Tumor Vaccine Group
1994-1999, Assistant Professor, University of Washington, Division of Oncology
1993-1994, Acting Instructor, University of Washington, Division of Oncology
1989-1990, Instructor, University of Illinois, Department of Medicine

Patents

Surface Receptor Antigen Vaccines, Patent Number: Application #60/109106, , , .
T cell therapy directed against the HER-2/neu protein, Patent Number: 5876712, , , .
Methods for eliciting or enhancing reactivity to HER-2/neu protein, Patent Number: 5869445, , , .
Methods and compositions to generate immunity in humans against self-tumor antigens by immunization with homologous foreign proteins, Patent Number: 5846538, , , .
Immune reactivity to HER-2/neu protein for diagnosis, Patent Number: 5726023, , , .
Theraputic Delivery Using Compounds Self-Assembled into High Axial Ratio Microstructures, Patent Number: 6180114, , , .
Compounds for eliciting or enhancing immune reactivity to the HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated, Patent Number: 6075122, , , .
Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the Her-2/neu oncogene is associated, Patent Number: 5801005, , , .

Funding Received

  • NCI: Mechanisms of Immunomodulatory and Anti-Tumor Actions of Polysaccharide Krestin, $250,000, 2007 to 2011.
  • NIH: Institute of Translational Health Sciences, $6,513,229, 2007 to 2012.
  • NCI: Developing a Serum Antibody-Based Assay for the Diagnosis of Colorectal Cancer, $30,000, 2007 to 2008.
  • Komen Foundation: Immunologic Signature in Early Stage Breast Cancer, $100,000, 2007 to 2011.
  • Department of Defense: Identification of Tumor Rejection Antigens Using a Mouse Tumor Rejection Model, $100,000, 2006 to 2009.
  • Arnold and Mabel Beckman Foundation: Phase I/II Study of Combination Immunotherapy in Advanced Stage Breast Cancer, $125,000, 2006 to 2008.
  • Ovarian Cancer Research Fund: Cooperative Ovarian Cancer Group for Immunotherapy, $107,811, 2005 to 2008.
  • Department of Defense: Phase II Study of HER-2/neu Intracellular Domain Peptide-Based Vaccine Administered to Stage IV HER2 Positive Breast Cancer Patients Receiving Trastuzumab, $300,000, 2004 to 2009.
  • NCI: Pacific Ovarian Cancer Research Consortium: Leadership Core, $151,964, 2004 to 2009.
  • NCI: Multi-antigen Vaccines for Breast Cancer Prevention, $225,000, 2003 to 2008.
  • NCI: Phase I Clinical Trial of a HER2 ICD Plasmid Based DNA Vaccine in Patients with HER2 Overexpressing Breast and Ovarian Cancer, $904,715, 2003 to 2008.

Publications

  • Behrens MD, Wagner WM, Krco CJ, Erskine CL, Kalli KR, Krempski J, Gad EA, Disis ML, Knutson KL (Feb 2008) The endogenous danger signal, crystalline uric acid, signals for enhanced antibody immunity., Blood, 111 (3), 1472-9 Abstract
  • Coveler AL, Goodell V, Webster DJ, Salazar LG, Fintak PA, Childs JS, Higgins DM, Disis ML (Jan 2008) Common adjuvant breast cancer therapies do not inhibit cancer vaccine induced T cell immunity., Breast cancer research and treatment Abstract
  • Siebert JC, Inokuma M, Waid DM, Pennock ND, Vaitaitis GM, Disis ML, Dunne JF, Wagner DH, Maecker HT (Dec 2007) An analytical workflow for investigating cytokine profiles. Abstract
  • Salazar LG, Coveler AL, Swensen RE, Gooley TA, Goodell V, Schiffman K, Disis ML (Dec 2007) Kinetics of tumor-specific T-cell response development after active immunization in patients with HER-2/neu overexpressing cancers., Clinical immunology (Orlando, Fla.), 125 (3), 275-80 Abstract
  • Inokuma M, dela Rosa C, Schmitt C, Haaland P, Siebert J, Petry D, Tang M, Suni MA, Ghanekar SA, Gladding D, Dunne JF, Maino VC, Disis ML, Maecker HT (Aug 2007) Functional T cell responses to tumor antigens in breast cancer patients have a distinct phenotype and cytokine signature., Journal of immunology (Baltimore, Md. : 1950), 179 (4), 2627-33 Abstract
  • Wang LX, Shu S, Disis ML, Plautz GE (Jun 2007) Adoptive transfer of tumor-primed, in vitro-activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response., Blood, 109 (11), 4865-76 Abstract
  • Dang Y, Knutson KL, Goodell V, dela Rosa C, Salazar LG, Higgins D, Childs J, Disis ML (Mar 2007) Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming., Clinical cancer research : an official journal of the American Association for Cancer Research, 13 (6), 1883-91 Abstract
  • Goodell V, dela Rosa C, Slota M, MacLeod B, Disis ML (2007) Sensitivity and specificity of tritiated thymidine incorporation and ELISPOT assays in identifying antigen specific T cell immune responses., BMC immunology, 8, 21 Abstract
  • Ghanekar SA, Bhatia S, Ruitenberg JJ, DeLa Rosa C, Disis ML, Maino VC, Maecker HT, Waters CA (2007) Phenotype and in vitro function of mature MDDC generated from cryopreserved PBMC of cancer patients are equivalent to those from healthy donors., Journal of immune based therapies and vaccines, 5, 7 Abstract
  • Benz CC, Fedele V, Xu F, Ylstra B, Ginzinger D, Yu M, Moore D, Hall RK, Wolff DJ, Disis ML, Eppenberger-Castori S, Eppenberger U, Schittulli F, Tommasi S, Paradiso A, Scott GK, Albertson DG (Nov 2006) Altered promoter usage characterizes monoallelic transcription arising with ERBB2 amplification in human breast cancers., Genes, chromosomes & cancer, 45 (11), 983-94 Abstract
  • Lu H, Knutson KL, Gad E, Disis ML (Oct 2006) The tumor antigen repertoire identified in tumor-bearing neu transgenic mice predicts human tumor antigens., Cancer research, 66 (19), 9754-61 Abstract
  • Knutson KL, Lu H, Stone B, Reiman JM, Behrens MD, Prosperi CM, Gad EA, Smorlesi A, Disis ML (Aug 2006) Immunoediting of cancers may lead to epithelial to mesenchymal transition., Journal of immunology (Baltimore, Md. : 1950), 177 (3), 1526-33 Abstract
  • Knutson KL, Dang Y, Lu H, Lukas J, Almand B, Gad E, Azeke E, Disis ML (Jul 2006) IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice., Journal of immunology (Baltimore, Md. : 1950), 177 (1), 84-91 Abstract
  • Manjili MH, Arnouk H, Knutson KL, Kmieciak M, Disis ML, Subjeck JR, Kazim AL (Apr 2006) Emergence of immune escape variant of mammary tumors that has distinct proteomic profile and a reduced ability to induce "danger signals"., Breast cancer research and treatment, 96 (3), 233-41 Abstract
  • Goodell V, Salazar LG, Urban N, Drescher CW, Gray H, Swensen RE, McIntosh MW, Disis ML (Feb 2006) Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer., Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 (5), 762-8 Abstract
  • Disis ML, dela Rosa C, Goodell V, Kuan LY, Chang JC, Kuus-Reichel K, Clay TM, Kim Lyerly H, Bhatia S, Ghanekar SA, Maino VC, Maecker HT (Jan 2006) Maximizing the retention of antigen specific lymphocyte function after cryopreservation., Journal of immunological methods, 308 (1-2), 13-8 Abstract
  • Thompson JA, Dissanayake SK, Ksander BR, Knutson KL, Disis ML, Ostrand-Rosenberg S (Jan 2006) Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain., Cancer research, 66 (2), 1147-54 Abstract
  • Zhang H, Knutson KL, Hellstrom KE, Disis ML, Hellstrom I (Jan 2006) Antitumor efficacy of CD137 ligation is maximized by the use of a CD137 single-chain Fv-expressing whole-cell tumor vaccine compared with CD137-specific monoclonal antibody infusion., Molecular cancer therapeutics, 5 (1), 149-55 Abstract
  • Wagner, W.M., Disis, M.L. (2006) Peptide vaccines for cancer treatment, The handbook of biologically active peptides, Burlington, MA, Elsevier, 72: 499-505 pages (bookchapter)
  • Yang J, Huston L, Berger D, Danke NA, Liu AW, Disis ML, Kwok WW (Sep 2005) Expression of HLA-DP0401 molecules for identification of DP0401 restricted antigen specific T cells., Journal of clinical immunology, 25 (5), 428-36 Abstract
  • Goodell V, Disis ML (Apr 2005) Human tumor cell lysates as a protein source for the detection of cancer antigen-specific humoral immunity., Journal of immunological methods, 299 (1-2), 129-38 Abstract
  • Montgomery RB, Makary E, Schiffman K, Goodell V, Disis ML (Jan 2005) Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinase., Cancer research, 65 (2), 650-6 Abstract
  • Maecker HT, Moon J, Bhatia S, Ghanekar SA, Maino VC, Payne JK, Kuus-Reichel K, Chang JC, Summers A, Clay TM, Morse MA, Lyerly HK, DeLaRosa C, Ankerst DP, Disis ML (2005) Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT., BMC immunology, 6, 17 Abstract
  • Wallden B, Emond M, Swift ME, Disis ML, Swisshelm K (2005) Antimetastatic gene expression profiles mediated by retinoic acid receptor beta 2 in MDA-MB-435 breast cancer cells., BMC cancer, 5, 140 Abstract
  • Disis, M.L., Maeker, H.T., Clay, T.M., Lyerly, H.K., Chang, J.C.C. (2005) Immunologic Monitoring to Assess Immunity to Solid Tumors, Measuring Immunity: The Immunologic Surrogates Handbook, Academic Press, 40: 465-472 pages (bookchapter)
  • Disis ML, Goodell V, Schiffman K, Knutson KL (Sep 2004) Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients., Journal of clinical immunology, 24 (5), 571-8 Abstract
  • Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W (Sep 2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival., Nature medicine, 10 (9), 942-9 Abstract
  • Disis ML, Schiffman K, Guthrie K, Salazar LG, Knutson KL, Goodell V, dela Rosa C, Cheever MA (May 2004) Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccine., Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 (10), 1916-25 Abstract
  • Knutson KL, Disis ML (Feb 2004) IL-12 enhances the generation of tumour antigen-specific Th1 CD4 T cells during ex vivo expansion., Clinical and experimental immunology, 135 (2), 322-9 Abstract
  • Knutson KL, Almand B, Dang Y, Disis ML (Feb 2004) Neu antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic mice., Cancer research, 64 (3), 1146-51 Abstract
  • Disis, M.L., Salazar, L., Knutson, K.L. (2004) Peptide based vaccines in breast cancer, in Immunology of Breast Cancer, Breast Disease, IOS Press, 15: 1-9 pages (bookchapter)
  • Disis, M.L., Schiffman, K., Salazar, L, Knutson, K.L. (2004) Immunology and immunotherapy of breast cancer, Diseases of the Breast, Philadelphia, PA., Lippincott (bookchapter)
  • Berger, C.M., Knutson, K.L., Salazar, L.G., Schiffman, K., Disis, M.L. (2004) Peptide-Based Vaccines. Handbook of Cancer Vaccines, Cancer Drug Discovery and Development, Totowa, NJ, Humana Press, 10: 121-135 pages (bookchapter)
  • Salazar LG, Fikes J, Southwood S, Ishioka G, Knutson KL, Gooley TA, Schiffman K, Disis ML (Nov 2003) Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles., Clinical cancer research : an official journal of the American Association for Cancer Research, 9 (15), 5559-65 Abstract
  • Disis ML, Scholler N, Dahlin A, Pullman J, Knutson KL, Hellström KE, Hellström I (Oct 2003) Plasmid-based vaccines encoding rat neu and immune stimulatory molecules can elicit rat neu-specific immunity., Molecular cancer therapeutics, 2 (10), 995-1002 Abstract
  • Ginsburg AS, Salazar LG, True LD, Disis ML (Mar 2003) Fatal Bacillus cereus sepsis following resolving neutropenic enterocolitis during the treatment of acute leukemia., American journal of hematology, 72 (3), 204-8 Abstract
  • McNeel DG, Knutson KL, Schiffman K, Davis DR, Caron D, Disis ML (Jan 2003) Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvant., Journal of clinical immunology, 23 (1), 62-72 Abstract
  • Disis ML, Shiota FM, McNeel DG, Knutson KL (2003) Soluble cytokines can act as effective adjuvants in plasmid DNA vaccines targeting self tumor antigens., Immunobiology, 207 (3), 179-86 Abstract
  • Disis, M.L., Knutson, K.L., Salazar, L.G., Schiffman, K. (2003) Antigen specific cancer vaccines. In: Perry MC, ed., ASCO Educational Book, Alexandria, VA, American Society of Clinical Oncology, 29-36 pages (bookchapter)
  • Disis, M.L., Rivkin, S. (2003) Future directions in the management of ovarian cancer, Hematology/Oncology Clinics of North America, WB Saunders, 17 (4): 1075-1085 pages (bookchapter)
  • Knutson KL., Curiel ,T.J., Salazar, L., Disis, M.L. (2003) Immunologic principles and immunotherapeutic approaches in ovarian cancer, Hematology/Oncology Clinics of North America, WB Saunders, 17 (4): 1051-1073 pages (bookchapter)
  • Disis, M.L., Schiffman, K., Salazar, L.G., Almand, B., Knutson, K.L. (2003) HER-2/neu Vaccines, Cancer Chemotherapy and Biological Response Modifiers-Annual 21, Elsevier Science, 13: 275-285 pages (bookchapter)
  • Schiffman K, Rinn K, Disis ML (Jul 2002) Delayed type hypersensitivity response to recall antigens does not accurately reflect immune competence in advanced stage breast cancer patients., Breast cancer research and treatment, 74 (1), 17-23 Abstract
  • Knutson KL, Disis ML (Jul 2002) Clonal diversity of the T-cell population responding to a dominant HLA-A2 epitope of HER-2/neu after active immunization in an ovarian cancer patient., Human immunology, 63 (7), 547-57 Abstract
  • Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, Knutson KL, Schiffman K (Jun 2002) Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines., Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 (11), 2624-32 Abstract
  • Knutson KL, Schiffman K, Cheever MA, Disis ML (May 2002) Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity., Clinical cancer research : an official journal of the American Association for Cancer Research, 8 (5), 1014-8 Abstract
  • Disis ML, Rinn K, Knutson KL, Davis D, Caron D, dela Rosa C, Schiffman K (Apr 2002) Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers., Blood, 99 (8), 2845-50 Abstract
  • Knutson, K.L., Bishop, M.R., Schiffman, K., Disis, M.L. (2002) Immunotherapy for Breast Cancer, Cancer Chemotherapy and Biologic Response Modifiers- Annual 20, Elsevier Science, 20:351-69 pages (bookchapter)
  • Salazar, L., Disis, M.L. (2002) Antibody responses to human tumor oncoproteins in cancer patients, Tumor antigens recognized by T cells and antibodies, H. Stauss and Y. Kaw Edition, Harwood Academic Publishers, 11: 172-190 pages (bookchapter)
  • Schiffman, K, Disis, M.L (2002) Update on vaccines for breast cancer, Diseases of the Breast Updates, Harris, J.R. and Lip Edition, Philadelphia, PA, Lippincott, 2: 1-14 pages (bookchapter)
  • McNeel DG, Nguyen LD, Disis ML, Identification of T helper epitopes from prostatic acid phosphatase, Cancer Research, 61(13), 5161-7, 2001 Abstract
  • McNeel DG, Nguyen LD, Ellis WJ, Higano CS, Lange PH, Disis ML, Naturally occurring prostate cancer antigen-specific T cell responses of a Th1 phenotype can be detected in patients with prostate cancer, Prostate, 47(3), 222-9, 2001 Abstract
  • Knutson KL and Disis ML, Expansion of HER-2/neu specific T cells exvivo following immunization with a HER-2/neu peptide based vaccine, Journal of Clinical Investigation, 2, 73-79, 2001
  • Knutson KL, Schiffman K, and Disis ML, Generation of HER-2/neu CD8+ T cell immunity in cancer patients following immunization with a HER-2/neu helper peptide vaccine, Journal of Clinical Investigation, 107, 477-484, 2001
  • McNeel DG, Nguyen LD, and Disis ML, Identification of T helper epitopes derived from prostatic acid phosphate, Cancer Research, 61(13), 5161-5167, 2001
  • McNeel DG, Nguyen LD, Storer BE, Vessella R, Lange PH, Disis ML, Antibody immunity to prostate cancer associated antigens can be detected in the serum of patients with prostate cancer, Journal of Urology, 164(5), 1825-9, November 2000 Abstract
  • Disis ML, Knutson KL, Schiffman K, Rinn K, McNeel DG, Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer, Breast Cancer Research and Treatment, 62(3), 245-52, August 2000 Abstract
  • Gaiger A, Reese V, Disis ML, Cheever MA (Aug 2000) Immunity to WT1 in the animal model and in patients with acute myeloid leukemia., Blood, 96 (4), 1480-9 Abstract
  • Disis ML, Knutson KL, Schiffman K, Rinn K, McNeel DG (Aug 2000) Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer., Breast cancer research and treatment, 62 (3), 245-52 Abstract
  • Disis ML, Schiffman K, Gooley TA, McNeel DG, Rinn K, Knutson KL, Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization, Clinical Cancer Research, 6(4), 1347-50, April 2000 Abstract
  • Bernhard H, Huseby ES, Hand SL, Lohmann M, Batten WY, Disis ML, Gralow JR, Meyer zum Büschenfelde KH, Ohlén C, Cheever MA (Apr 2000) Dendritic cells lose ability to present protein antigen after stimulating antigen-specific T cell responses, despite upregulation of MHC class II expression., Immunobiology, 201 (5), 568-82 Abstract
  • Cheever, M.A., Disis, M.L. (2000) Immunology and immunotherapy of breast cancer, Diseases of the Breast, Lippman, Morrow and Edition, Philadelphia, PA, Lippincott, 11: 172-190 pages (bookchapter)
  • Disis, M.L., Cheever, M.A. (2000) Clinical trials of HER-2/neu peptide based vaccines, Peptide-Based Cancer Vaccines, W. Martin Kast (Ed), Georgetown, Texas, Landes Bioscience, 24: 143-154 pages (bookchapter)
  • Knutson KL, Schiffman K, Rinn K, Disis ML, Immunotherapeutic approaches for the treatment of breast cancer, Journal of Mammary Gland Biology and Neoplasia, 4(4), 353-65, October 1999 Abstract
  • Rinn K, Schiffman K, Otero HO, Disis ML (Jul 1999) Antigen-specific recall urticaria to a peptide-based vaccine., The Journal of allergy and clinical immunology, 104 (1), 240-2 Abstract
  • Disis ML, Grabstein KH, Sleath PR, Cheever MA, Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine, Clinical Cancer Research, 5(6), 1289-97, June 1999 Abstract
  • Disis ML, Grabstein KH, Sleath PR, Cheever MA, Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine, Clinical Cancer Research, 5(6), 1289-97, June 1999
  • Ward RL, Hawkins NJ, Coomber D, Disis ML (Jun 1999) Antibody immunity to the HER-2/neu oncogenic protein in patients with colorectal cancer., Human immunology, 60 (6), 510-5 Abstract
  • McNeel DG, Schiffman K, Disis ML, Immunization with recombinant human granulocyte-macrophage colony-stimulating factor as a vaccine adjuvant elicits both a cellular and humoral response to recombinant human granulocyte-macrophage colo, Blood, 93(8), 2653-9, 1999 Abstract
  • Disis ML, McNeel DG, Schiffman K, Rinn K, and Knutson KL, Peptide based tumor vaccines, Current Opinion in Oncologic, Endocrine, and Metabolic Drugs, 1(3), 253-259, 1999
  • Disis M L, Shiota F M, Cheever M A, Human HER-2/neu protein immunization circumvents tolerance to rat neu: a vaccine strategy for 'self' tumour antigens, Immunology, 93(2), 192-9, February 1998 Abstract
  • Disis M L, Cheever M A, HER-2/neu oncogenic protein: issues in vaccine development, Critical Reviews In Immunology, 18(1-2), 37-45, 1998 Abstract
  • Schoof DD, Smith JW 2nd, Disis ML, Brant-Zawadski P, Wood W, Doran T, Johnson E, Urba WJ, Immunization of metastatic breast cancer patients with CD80-modified breast cancer cells and GM-CSF, Advanced Experimental Medicine and Biology, 451, 511-8, 1998 Abstract
  • Disis M L, Pupa S M, Gralow J R, Dittadi R, Menard S, Cheever M A, High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer, Journal of Clinical Oncology, 15(11), 3363-7, November 1997 Abstract
  • Lustgarten J, Theobald M, Labadie C, LaFace D, Peterson P, Disis M L, Cheever M A, Sherman L A, Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8, Human Immunology, 52(2), 109-18, February 1997 Abstract
  • Lustgarten J, Theobald M, Labadie C, LaFace D, Peterson P, Disis ML, Cheever MA, Sherman LA (Feb 1997) Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8., Human immunology, 52 (2), 109-18 Abstract
  • Disis M L, Cheever M A, HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer, Advances In Cancer Research, 71, 343-71, 1997 Abstract
  • Hand S L, Bernhard H, Huseby E S, Rubin W D, Disis M L, Cheever M A, In vitro priming to tumor-associated proteins, Advances In Experimental Medicine and Biology, 417, 503-9, 1997 Abstract
  • Disis, M.L, Cheever, M.A. (1997) A target for antigen specific immunotherapy of human cancer, Adv in Cancer Research, Vande Woude, G.F. an Edition, San Diego, U.S.A., Academic Press, 71: 343-371 pages (bookchapter)
  • Disis M L, Cheever M A, Oncogenic proteins as tumor antigens, Current Opinion In Immunology, 8(5), 637-42, October 1996 Abstract
  • Disis M L, Bernhard H, Shiota F M, Hand S L, Gralow J R, Huseby E S, Gillis S, Cheever M A, Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines, Blood, 88(1), 202-10, 1 Jul 1996 Abstract
  • Disis M L, Gralow J R, Bernhard H, Hand S L, Rubin W D, Cheever M A, Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein, Journal of Immunology, 156(9), 3151-8, 1 May 1996 Abstract
  • Takahashi M, Chen W, Byrd DR, Disis ML, Huseby ES, Qin H, McCahill L, Nelson H, Shimada H, Okuno K, et al, Antibody to ras proteins in patients with colon cancer, Clinical Cancer Research, 1(10), 1071-7, October 1995 Abstract
  • Qin H, Chen W, Takahashi M, Disis M L, Byrd D R, McCahill L, Bertram K A, Fenton R G, Peace D J, Cheever M A, CD4+ T-cell immunity to mutated ras protein in pancreatic and colon cancer patients, Cancer Research, 55(14), 2984-7, 15 Jul 1995 Abstract
  • Cheever M A, Disis M L, Bernhard H, Gralow J R, Hand S L, Huseby E S, Qin H L, Takahashi M, Chen W, Immunity to oncogenic proteins, Immunological Reviews, 145, 33-59, June 1995 Abstract
  • Bernhard H, Disis M L, Heimfeld S, Hand S, Gralow J R, Cheever M A, Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood, Cancer Research, 55(5), 1099-104, 1 Mar 1995 Abstract
  • Disis M L, Smith J W, Murphy A E, Chen W, Cheever M A, In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein, Cancer Research, 54(4), 1071-6, 15 Feb 1994 Abstract
  • Disis M L, Calenoff E, McLaughlin G, Murphy A E, Chen W, Groner B, Jeschke M, Lydon N, McGlynn E, Livingston R B, et al, Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer, Cancer Research, 54(1), 16-20, 1 Jan 1994 Abstract
  • Disis M L, Bernhard H, Gralow J R, Hand S L, Emery S R, Calenoff E, Cheever M A, Immunity to the HER-2/neu oncogenic protein, Ciba Foundation Symposium, 187, 198-207; discussion, 1994 Abstract
  • Disis, M.L., Bernhard, H., Gralow, J.R., Hand, S.L., Emery, S.R., Calenoff, E., Cheever, M.A. (1994) Immunity to the HER-2/neu oncogenic protein, Vaccines Against Virally Induced Cancers, Ciba Foundation Symp Edition, Baffins Lane, Chichester, U.K., John Wiley & Sons, Inc., 187: 198-211 pages (bookchapter)
  • Peace, D.J., Disis, M.L., Chen, W., Cheever, M.A (1994) IL-2 in the induction and expansion of tumor specific immunity, Cytokine-Induced Tumor Immunogencity, G. Forni, R. Foa, A. Edition, Academic Press (bookchapter)
  • Cheever, M.A., Chen, W., Disis, M.L., Peace, D.J (1994) Overview of specific T cell therapy, Immunobiology of Renal Cell Carcinoma, Drs. Klein, Bukowski Edition, Marcel Dekker, Inc. (bookchapter)
  • Cheever M A, Chen W, Disis M L, Takahashi M, Peace D J, T-cell immunity to oncogenic proteins including mutated ras and chimeric bcr-abl, Annals of The New York Academy of Sciences, 690, 101-12, 12 Aug 1993 Abstract
  • Peace D J, Smith J W, Disis M L, Chen W, Cheever M A, Induction of T cells specific for the mutated segment of oncogenic P21ras protein by immunization in vivo with the oncogenic protein, Journal of Immunotherapy, 14(2), 110-4, August 1993 Abstract
  • Cheever, M.A, Chen, W, Disis, M.L., Takahashi, M., Peach, D.J. (1993) T-cell immunity to oncogenic proteins including mutated ras and chimeric bcr-abl., Specific Immunotherapy of Cancer with Vaccines, New York Academy of Sciences, Drs. Bystryn, Ferrone & Livingston (eds.), 101-112 pages (bookchapter)
  • Disis ML, McDonald TL, Colombo JL, Kobayashi RH, Angle CR, Murray S (May 1986) Circulating immune complexes in cystic fibrosis and their correlation to clinical parameters., Pediatric research, 20 (5), 385-90 Abstract
  • Dols A, Meijer SL, Hu HM, Goodell V, Disis ML, Von Mensdorff-Pouilly S, Verheijen R, Alvord WG, Smith JW, Urba WJ, Fox BA, Identification of tumor-specific antibodies in patients with breast cancer vaccinated with gene-modified allogeneic tumor cells., Journal of immunotherapy (Hagerstown, Md. : 1997), 26 (2), 163-70 Abstract

Profile Details

Last Updated: 6/1/2009

COS Expertise ID #1144993
Reference this profile directly: http://myprofile.cos.com/NDisis